This activity has expired. Thank you for using WebBasedCME.com. Continue to check our activities page for additional online CME offerings .

Post-Test - Peak Issues (Issue 2): Clinical Use Of Incretin-Based Therapies To Treat Type 2 Diabetes

INSTRUCTIONS: Select the most appropriate response. To receive credit, participants must earn a score of 70% or higher.

0. Have you created an account on WebBasedCME.com? You must register and be signed in to participate and receive CME credit for this activity.

1.	The incretin effect is ____________ in patients with type 2 diabetes, which contributes to abnormal control of ____________.
A:		Increased; postmeal glucose
B:		Decreased; fasting glucose
C:		Increased; fasting glucose
D:		Decreased; postmeal glucose

2.	Metabolism of native GLP-1 by the DPP-4 enzyme results in a half-life of:
A:		1-2 minutes
B:		12 hours
C:		7 minutes
D:		36 hours

3.	GLP-1 has all of the following beneficial effects in type 2 diabetes except:
A:		Inhibition of glucagon secretion
B:		Stimulation of islet cell neogenesis
C:		Decrease in cardiac output
D:		Increase in satiety

4.	DPP-4 inhibitors have been shown to:
A:		Cause a decline in -cell mass and function
B:		Contribute to an increase in -cell mass and function
C:		Have no effect on the cell
D:		Contribute to an increase in -cell mass, with no impact on -cell function

5.	In monotherapy clinical trials, DPP-4 inhibitors have resulted in A1C decreases of:
A:		– 0.5% to – 0.8%
B:		– 0.2% to – 0.4%
C:		– 0.7% to – 1.0%
D:		– 1.0% to – 1.2%

6.	DPP-4 inhibitors have been studied in combination with all of the following agents except:
A:		Metformin
B:		Insulin
C:		GLP-1 receptor agonists
D:		Thiazolidinediones

7.	Combination therapy with DPP-4 inhibitors has resulted in PPG reductions of:
A:		– 0.5 to – 2.0 mmol/L
B:		– 5.0 to – 9.2 mmol/L
C:		– 0.2 to – 1.0 mmol/L
D:		– 0.9 to – 5.2 mmol/L

8.	DPP-4 inhibitors have a ____________ effect on weight and a potential ____________ effect on cardiovascular parameters in patients with type 2 diabetes.
A:		Neutral; beneficial
B:		Negative; detrimental
C:		Positive; detrimental
D:		Negative; beneficial

9.	Adverse events with DPP-4 inhibitors consist mostly of:
A:		Gastrointestinal events and hypoglycemia
B:		Headaches and gastrointestinal events
C:		Headaches and non–life-threatening infections
D:		Non–life-threatening infections and hypoglycemia

10.	The American Association of Clinical Endocrinologists/American College of Endocrinology guidelines recommend DPP-4 inhibitors for use in treatment-naïve patients with A1C < _______ and in treatment-experienced patients with A1C between _______.
A:		8.0%; 6.5% and 8.5%
B:		9.0%; 6.5% and 8.5%
C:		8.5%; 6.5% and 8.5%
D:		9.0%; 7.0% and 8.0%